Shots:
- Novartis has reported topline data from P-III (REMODEL-1/-2) trials assessing remibrutinib (100mg) vs teriflunomide in ~2,000 adults with relapsing multiple sclerosis (RMS)
- Remibrutinib met the 1EP, significantly reducing annualized relapse rate (ARR), plus trial showed clinically meaningful reductions in key 2EPs related to disability progression, with a positive trend in 3mCDP & nominally significant improvement in 6mCDP in the preplanned combined analysis; data to be presented at MSToronto2026
- Remibrutinib is a highly selective, potent oral BTK inhibitor, with Novartis planning to seek global regulatory approval for its use in RMS
Ref: Globenewswire | Image: Novartis | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
